JPWO2020135674A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020135674A5 JPWO2020135674A5 JP2021537771A JP2021537771A JPWO2020135674A5 JP WO2020135674 A5 JPWO2020135674 A5 JP WO2020135674A5 JP 2021537771 A JP2021537771 A JP 2021537771A JP 2021537771 A JP2021537771 A JP 2021537771A JP WO2020135674 A5 JPWO2020135674 A5 JP WO2020135674A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nos
- amino acid
- acid sequences
- cdr2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 954
- 150000001413 amino acids Chemical class 0.000 claims description 25
- 238000006467 substitution reaction Methods 0.000 claims description 16
- 102000002029 Claudin Human genes 0.000 claims description 4
- 108050009302 Claudin Proteins 0.000 claims description 4
- 241001529936 Murinae Species 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 description 7
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024103100A JP7724332B2 (ja) | 2018-12-28 | 2024-06-26 | クローディン１８．２結合部分およびその利用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018125052 | 2018-12-28 | ||
| CNPCT/CN2018/125052 | 2018-12-28 | ||
| CNPCT/CN2019/095827 | 2019-07-12 | ||
| CN2019095827 | 2019-07-12 | ||
| PCT/CN2019/129017 WO2020135674A1 (en) | 2018-12-28 | 2019-12-27 | Claudin18.2 binding moieties and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024103100A Division JP7724332B2 (ja) | 2018-12-28 | 2024-06-26 | クローディン１８．２結合部分およびその利用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022515487A JP2022515487A (ja) | 2022-02-18 |
| JPWO2020135674A5 true JPWO2020135674A5 (enExample) | 2022-11-24 |
Family
ID=71127698
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021537771A Pending JP2022515487A (ja) | 2018-12-28 | 2019-12-27 | クローディン１８．２結合部分およびその利用 |
| JP2024103100A Active JP7724332B2 (ja) | 2018-12-28 | 2024-06-26 | クローディン１８．２結合部分およびその利用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024103100A Active JP7724332B2 (ja) | 2018-12-28 | 2024-06-26 | クローディン１８．２結合部分およびその利用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12258418B2 (enExample) |
| EP (1) | EP3902839A4 (enExample) |
| JP (2) | JP2022515487A (enExample) |
| KR (1) | KR20210110339A (enExample) |
| CN (1) | CN113227146B (enExample) |
| AU (1) | AU2019415848A1 (enExample) |
| BR (1) | BR112021012608A2 (enExample) |
| CA (1) | CA3125193A1 (enExample) |
| IL (1) | IL284393A (enExample) |
| MX (1) | MX2021007939A (enExample) |
| SG (1) | SG11202106534RA (enExample) |
| WO (1) | WO2020135674A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7407841B2 (ja) * | 2019-05-16 | 2024-01-04 | 斉魯制薬有限公司 | クローディン１８ａ２に対する抗体及びその応用 |
| KR102649942B1 (ko) | 2019-11-05 | 2024-03-25 | 라노바 메디신즈 리미티드 컴파니 | 클라우딘 18.2를 표적화하는 항체-약물 콘쥬게이트 |
| CN113637082A (zh) * | 2020-04-27 | 2021-11-12 | 启愈生物技术(上海)有限公司 | 一种靶向人claudin和人PDL1蛋白的双特异抗体及其应用 |
| CN115698072B (zh) | 2020-07-01 | 2023-07-04 | 山东博安生物技术股份有限公司 | 抗gpc3抗体，抗gpc3嵌合抗原受体和gpc3/cd3双特异性抗体 |
| CN113929780A (zh) * | 2020-07-13 | 2022-01-14 | 北京凯因科技股份有限公司 | 一种结合密蛋白的用于治疗癌症的人源化抗体 |
| JP2023544140A (ja) * | 2020-09-28 | 2023-10-20 | エルピサイエンス（スーチョウ）・バイオファーマ，リミテッド | 新規の抗クローディン１８抗体 |
| EP4240415A1 (en) | 2020-11-08 | 2023-09-13 | Seagen Inc. | Combination-therapy antibody drug conjugate with immune cell inhibitor |
| CN114539402B (zh) * | 2020-11-27 | 2025-06-13 | 南京北恒生物科技有限公司 | 靶向Claudin18.2的抗体及其用途 |
| WO2022111633A1 (en) * | 2020-11-27 | 2022-06-02 | Sunshine Lake Pharma Co., Ltd. | Cldn18.2 antibody and use thereof |
| WO2022122709A1 (en) | 2020-12-07 | 2022-06-16 | Sotio Biotech A.S. | Antibody-drug conjugates based on humanized cldn18.2 antibodies |
| PE20231561A1 (es) | 2020-12-23 | 2023-10-03 | Sotio Biotech A S | Conjugados anticuerpo-farmaco especificos para tumores con claudina 18.2 |
| CN113321730B (zh) * | 2021-01-11 | 2023-10-10 | 上海莱馥医疗科技有限公司 | Cldn18.2抗体及其应用 |
| WO2022166940A1 (en) * | 2021-02-08 | 2022-08-11 | Shandong Boan Biotechnology Co., Ltd. | Cldn18.2/cd3 bispecific antibodies for the therapy of cldn18.2-expressing solid tumors |
| CN115109154A (zh) * | 2021-03-17 | 2022-09-27 | 三优生物医药(上海)有限公司 | 一种靶向cldn18.2的抗体或其抗原结合片段及其应用 |
| EP4299593A4 (en) * | 2021-04-02 | 2025-12-10 | Oricell Therapeutics Co Ltd | CLDN18.2 ANTIGEN-BINDING PROTEIN AND ITS USE |
| US20230272109A1 (en) * | 2021-05-08 | 2023-08-31 | Remegen Co., Ltd. | Anti-claudin 18.2 antibody and antibody-drug conjugate thereof |
| EP4488290A1 (en) | 2022-03-04 | 2025-01-08 | ABTIS Co., Ltd. | Method for increasing production yield of antibody-drug conjugate by using thiol-reactive additive |
| KR20240117111A (ko) | 2022-11-01 | 2024-07-31 | 앱티스 주식회사 | Fc 결합성 유닛을 포함하는 화합물 및 이를 이용하여 제조된 컨쥬게이트 |
| AU2024210908A1 (en) | 2023-01-18 | 2025-08-21 | Tyligand Bioscience (Shanghai) Limited | Antibody-drug conjugate and use thereof |
| CN116284224B (zh) * | 2023-05-12 | 2023-07-25 | 中国农业大学 | 一种结合Claudin 18.2的环肽及其应用 |
| WO2025038602A1 (en) * | 2023-08-14 | 2025-02-20 | Ginkgo Bioworks, Inc. | Immune cell stimulatory sequences |
| WO2025059162A1 (en) | 2023-09-11 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Car-engager containing il-2 variants to enhance the functionality of car t cells |
| WO2025072299A1 (en) * | 2023-09-25 | 2025-04-03 | Duke University | Compositions comprising hiv envelopes to induce hiv-1 antibodies |
| CN120829517A (zh) * | 2024-04-22 | 2025-10-24 | 鲁南新时代生物技术有限公司 | 抗cldn18.2/cd3双特异性抗体及用途 |
| WO2025251228A1 (en) | 2024-06-05 | 2025-12-11 | Nuwacell Biotechnologies Co., Ltd. | Cldn18.2-targeting chimeric antigen receptor and engineered cell |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1790664A1 (en) * | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| EP1997832A1 (en) * | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
| WO2013174403A1 (en) | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2013174404A1 (en) * | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2014127785A1 (en) | 2013-02-20 | 2014-08-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| CN120518772A (zh) * | 2014-07-17 | 2025-08-22 | 恺兴生命科技(上海)有限公司 | 靶向cld18a2的t淋巴细胞及其制备方法和应用 |
| WO2016165762A1 (en) * | 2015-04-15 | 2016-10-20 | Ganymed Pharmaceuticals Ag | Drug conjugates comprising antibodies against claudin 18.2 |
| WO2016180468A1 (en) * | 2015-05-11 | 2016-11-17 | Biontech Cell & Gene Therapies Gmbh | Claudin-18.2-specific immunoreceptors and t cell epitopes |
| JP7587921B2 (ja) * | 2016-07-08 | 2024-11-21 | クレージュ メディカル カンパニー，リミテッド | 抗クローディンタンパク質１８ａ２の抗体及びその応用 |
| WO2019173420A1 (en) * | 2018-03-08 | 2019-09-12 | Phanes Therapeutics, Inc. | Anti-claudin 18.2 antibodies and uses thereof |
| AU2019270865B2 (en) * | 2018-05-18 | 2023-03-30 | LaNova Medicines Limited | Anti-claudin 18.2 antibodies and uses thereof |
| US11407828B2 (en) * | 2019-02-01 | 2022-08-09 | Novarock Biotherapeutics, Ltd. | Anti-CLauDiN 18 antibodies and methods of use thereof |
| BR112022003147A2 (pt) * | 2019-08-20 | 2022-05-17 | Suzhou Transcenta Therapeutics Co Ltd | Novos anticorpos anti-cldn18.2 |
-
2019
- 2019-12-27 AU AU2019415848A patent/AU2019415848A1/en active Pending
- 2019-12-27 EP EP19906510.3A patent/EP3902839A4/en active Pending
- 2019-12-27 MX MX2021007939A patent/MX2021007939A/es unknown
- 2019-12-27 JP JP2021537771A patent/JP2022515487A/ja active Pending
- 2019-12-27 CA CA3125193A patent/CA3125193A1/en active Pending
- 2019-12-27 SG SG11202106534RA patent/SG11202106534RA/en unknown
- 2019-12-27 US US17/419,203 patent/US12258418B2/en active Active
- 2019-12-27 BR BR112021012608-2A patent/BR112021012608A2/pt unknown
- 2019-12-27 WO PCT/CN2019/129017 patent/WO2020135674A1/en not_active Ceased
- 2019-12-27 KR KR1020217023724A patent/KR20210110339A/ko active Pending
- 2019-12-27 CN CN201980085449.3A patent/CN113227146B/zh active Active
-
2021
- 2021-06-27 IL IL284393A patent/IL284393A/en unknown
-
2024
- 2024-06-26 JP JP2024103100A patent/JP7724332B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020135674A5 (enExample) | ||
| JP2020510422A5 (enExample) | ||
| JP2020062036A5 (enExample) | ||
| JP2019533719A5 (enExample) | ||
| TWI777056B (zh) | 結合至ssea4的單株抗體及其用途 | |
| JP2014158469A5 (enExample) | ||
| RU2019128134A (ru) | Антитело против gprc5d и молекула, содержащая антитело | |
| JP2015163068A5 (enExample) | ||
| JP2017514461A5 (enExample) | ||
| HRP20190605T1 (hr) | Protutijela anti-fxi i postupci njihove uporabe | |
| RU2016137110A (ru) | Антитела к компоненту комплемента с5 | |
| WO2008004834A1 (en) | Humanized monoclonal antibody highly binding to epidermal growth factor receptor, egf receptor | |
| JP2020522488A5 (enExample) | ||
| RU2009136677A (ru) | Рекомбинантные антитела для лечения респираторно-синцитиальных вирусных инфекций | |
| JPWO2020043152A5 (enExample) | ||
| JP2010509931A5 (enExample) | ||
| JP2024016024A5 (enExample) | ||
| US20250136720A1 (en) | Bispecific and tetravalent cd137 and fap molecules for the treatment of cancer | |
| JP2020502233A5 (enExample) | ||
| RU2016114074A (ru) | Анти-rspo антитела и способы применения | |
| JP2023182689A5 (enExample) | ||
| JP2024020436A5 (enExample) | ||
| IL277899B2 (en) | Methods and preparations for treating yellow fever | |
| JPWO2022067262A5 (enExample) | ||
| IL321677A (en) | Anti-PDL1 antibodies, multispecific antibodies, and methods of use |